Contributing Member of the Healthcare Councils

Names and details of certain GLG News authors are available only to GLG Clients and Council Members. GLG News authors are subject-matter experts within the GLG Councils and are available for expert consulting - by phone, in-person, or written analysis. To find out how to become a GLG client or Council Member, click here.

GLG News by this Author

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

New biomarker panel outperforms current standard for detecting early-stage ovarian cancer - reason for cautious optimism

January 8, 2009

Analysis of:New Diagnostic 98% Accurate Detecting Early Stage Ovarian Cancers - 2nd Generation OvPlex™ Panel Completes Initial Phase II Biomarker Trial | www.medicalnewstoday.com

A panel of biomarkers developed by the Australian diagnostic company Healthlinx was shown to outperform the existing standard of CA125 in detecting early-stage ovarian cancer in a Phase II biomarker trial (reported 'diagnostic efficiency' with the panel was over 98% compared to values around 60% for CA125). In addition, the panel was found to correctly identify a number of cases falsely classified (either positive or negative) by the CA125 test, a further confirmation of the power of a panel over a single marker. Future studies in larger trials will determine whether the panel is robust enough to hold up to expectations and whether the panel can be applied across ethnic boundaries.

Page : 11 to 1 of 1

Subscribe to Updates

By RSS